source
- UniQure prepares for FDA advisory committee on Huntington’s gene therapy amid rare-disease regulatory jittersUniQure said it is ready to present its Huntington's disease gene therapy, AMT-130, to an FDA advisory committee, as discussed in its Q2 earnings call. The company expects the FDA may schedule the…
- Analysts say Daiichi Sankyo’s ADC pipeline lags rivals as cash flow peaks, cutting expectationsJefferies analysts warned that Daiichi Sankyo's early‑stage antibody‑drug conjugate (ADC) pipeline is falling behind competitors, even as the company approaches a peak in cash flow from its existin…